A Study of HLX42 in Advanced/Metastatic Solid Tumors

This study tests a new drug called HLX42 in patients with advanced or metastatic solid tumors (various cancer types) that have stopped responding to standard treatments. The trial first finds a safe dose, then evaluates effectiveness in specific tumor types. **You may be eligible if...** - You are between 18 and 75 years old with a confirmed advanced or metastatic solid tumor - Your cancer has progressed on or you cannot tolerate standard treatments - You are in adequate general health - You have measurable or evaluable tumor lesions **You may NOT be eligible if...** - You have active brain metastases that are uncontrolled - You have serious heart, liver, or immune conditions - You have received recent prior treatments that conflict with this drug Talk to your doctor to see if this trial is right for you.